Mike Kratky
Stock Analyst at Leerink Partners
(2.73)
# 2,113
Out of 5,111 analysts
35
Total ratings
45.45%
Success rate
32.13%
Average return
Main Sectors:
Stocks Rated by Mike Kratky
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Outperform | $127 → $128 | $92.19 | +38.84% | 2 | Oct 1, 2025 | |
| INSP Inspire Medical Systems | Maintains: Market Perform | $116 → $97 | $119.26 | -18.67% | 7 | Aug 15, 2025 | |
| MDT Medtronic | Initiates: Outperform | $110 | $98.57 | +11.60% | 1 | Jun 16, 2025 | |
| BBNX Beta Bionics | Initiates: Outperform | $28 | $29.72 | -5.79% | 1 | Feb 24, 2025 | |
| TXG 10x Genomics | Downgrades: Market Perform | $25 → $12 | $15.76 | -23.86% | 2 | Feb 13, 2025 | |
| DXCM DexCom | Maintains: Outperform | $90 → $87 | $65.73 | +32.36% | 2 | Oct 25, 2024 | |
| PEN Penumbra | Initiates: Outperform | $263 | $309.15 | -14.93% | 1 | Sep 3, 2024 | |
| TNDM Tandem Diabetes Care | Upgrades: Outperform | $34 → $45 | $22.11 | +103.53% | 2 | Apr 25, 2024 | |
| NPCE NeuroPace | Initiates: Outperform | $22 | $15.92 | +38.19% | 1 | Jan 30, 2024 | |
| PODD Insulet | Initiates: Outperform | $184 | $291.51 | -36.88% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $42 | $36.49 | +15.10% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $342 | $559.52 | -38.88% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $75 | $83.38 | -10.05% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $37 | $36.10 | +2.49% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $9 | $29.78 | -69.78% | 1 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $325 → $50 | $31.60 | +58.23% | 2 | Aug 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $33 → $45 | $1.24 | +3,529.03% | 2 | Jan 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $145 → $315 | $560.55 | -43.81% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $26 → $31 | $85.68 | -63.82% | 2 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $26.00 | -46.15% | 1 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $40 | $33.03 | +21.10% | 1 | Aug 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $392 → $384 | $33.22 | +1,056.10% | 1 | Aug 11, 2022 |
Boston Scientific
Oct 1, 2025
Maintains: Outperform
Price Target: $127 → $128
Current: $92.19
Upside: +38.84%
Inspire Medical Systems
Aug 15, 2025
Maintains: Market Perform
Price Target: $116 → $97
Current: $119.26
Upside: -18.67%
Medtronic
Jun 16, 2025
Initiates: Outperform
Price Target: $110
Current: $98.57
Upside: +11.60%
Beta Bionics
Feb 24, 2025
Initiates: Outperform
Price Target: $28
Current: $29.72
Upside: -5.79%
10x Genomics
Feb 13, 2025
Downgrades: Market Perform
Price Target: $25 → $12
Current: $15.76
Upside: -23.86%
DexCom
Oct 25, 2024
Maintains: Outperform
Price Target: $90 → $87
Current: $65.73
Upside: +32.36%
Penumbra
Sep 3, 2024
Initiates: Outperform
Price Target: $263
Current: $309.15
Upside: -14.93%
Tandem Diabetes Care
Apr 25, 2024
Upgrades: Outperform
Price Target: $34 → $45
Current: $22.11
Upside: +103.53%
NeuroPace
Jan 30, 2024
Initiates: Outperform
Price Target: $22
Current: $15.92
Upside: +38.19%
Insulet
Oct 16, 2023
Initiates: Outperform
Price Target: $184
Current: $291.51
Upside: -36.88%
Oct 16, 2023
Initiates: Outperform
Price Target: $42
Current: $36.49
Upside: +15.10%
Oct 16, 2023
Initiates: Outperform
Price Target: $342
Current: $559.52
Upside: -38.88%
Oct 16, 2023
Initiates: Market Perform
Price Target: $75
Current: $83.38
Upside: -10.05%
Oct 16, 2023
Initiates: Outperform
Price Target: $37
Current: $36.10
Upside: +2.49%
Oct 16, 2023
Initiates: Outperform
Price Target: $9
Current: $29.78
Upside: -69.78%
Aug 15, 2023
Downgrades: Market Perform
Price Target: $325 → $50
Current: $31.60
Upside: +58.23%
Jan 24, 2023
Maintains: Outperform
Price Target: $33 → $45
Current: $1.24
Upside: +3,529.03%
Dec 20, 2022
Maintains: Outperform
Price Target: $145 → $315
Current: $560.55
Upside: -43.81%
Dec 15, 2022
Maintains: Market Perform
Price Target: $26 → $31
Current: $85.68
Upside: -63.82%
Nov 4, 2022
Maintains: Outperform
Price Target: $12 → $14
Current: $26.00
Upside: -46.15%
Aug 15, 2022
Maintains: Outperform
Price Target: $32 → $40
Current: $33.03
Upside: +21.10%
Aug 11, 2022
Maintains: Outperform
Price Target: $392 → $384
Current: $33.22
Upside: +1,056.10%